Perspective Therapeutics to present ASCO 2026 data for next-gen radiopharmaceuticals

The company will release close look at Phase 1/2a data for its 212Pb-based candidates targeting NETs and melanoma. These data, detailing efficacy and safety, could draw investor attention to the pipeline's potential to address unmet needs in solid tumors.